Invex Therapeutics Limited (ASX:IXC) Announces Positive Exenatide Results
Significant Findings from Collaboration
Invex Therapeutics Limited (ASX: IXC) has announced promising preliminary results from its collaboration with Tessara Therapeutics on the ADBrain™ platform. This 3D human brain model has established a foundational insight into the neurodegeneration process characteristic of Alzheimer’s Disease (AD).
Low and moderate doses of Exenatide demonstrated substantial improvements in neuronal cell survival, with a 24% increase in viability at low doses under oxidative stress conditions and a 45% increase at moderate doses replicating ferroptosis, a critical pathway in neuronal death associated with AD.
Dosage and Tolerance Findings
The analysis showed that Exenatide was well tolerated by ADBrain™ micro-tissues across a range of doses, from 1μM to 100μM over three days. Two validated assays confirmed no adverse effects on neural cells, highlighting the potential therapeutic benefits of Exenatide for a range of neurodegenerative diseases.
Key efficacy results include:
– A 24% increase in cell viability from low-dose Exenatide (0.1 μM) under oxidative stress conditions.
– A protective effect on cell membranes at lethal concentrations of hydrogen peroxide.
– A notable 45% increase in cell viability with a 10 μM moderate dose against ferroptosis.
Broader Implications for Alzheimer’s Disease
The findings support emerging clinical evidence that GLP-1 receptor agonists, including Exenatide, may provide neuroprotective effects against dementia, potentially aiding in reducing brain shrinkage that may affect memory and decision-making faculties.
The Company plans to continue its exploratory activities with Tessara to investigate Exenatide’s application in various neurological conditions, including traumatic brain injury.
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.